Propanc Biopharma (PPCB) Fundamental Analysis: Revenue, Earnings & Valuation

8.15 / 10

Outperform

Fundamentals are robust: interest coverage 35.1, PB‑ROE –0.61, revenue growth >130% YoY, inventory turnover 104. Positive scores on most factors, but current liabilities/total liabilities at 97% and Asset‑MV negative drag performance. Overall fundamental rating Outperform with an 8.2/10 score.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight51.65%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.71%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-5.89%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value97.43

Score0/3

Weight-21.83%

1M Return-4.96%

PB-ROE

Value-0.61

Score3/3

Weight65.06%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.05

Score2/3

Weight-1.83%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.99%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.29%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-5.66%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight23.48%

1M Return4.00%

Is PPCB undervalued or overvalued?

PPCB scores 8.15/10 on fundamentals and holds a Discounted valuation at present. Backed by its -69.89% ROE, 0.00% net margin, -0.03 P/E ratio, 0.20 P/B ratio, and -97.78% earnings growth, these metrics solidify its Outperform investment rating.